A122 COMBINATION BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: THE CALGARY EXPERIENCE

BACKGROUND: Biologic therapy has revolutionized inflammatory bowel disease (IBD) care. More recently, newer biologics have been approved. Despite multiple options, clinical remission rates at one year are approximately 40% for any single biologic agent. In addition, questions surround the efficacy o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Can Assoc Gastroenterol
Autors principals: Panaccione, N, Novak, K L, Seow, C, Devlin, S, Lu, C, Heatherington, J, Kaplan, G G, Panaccione, R
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Posters Of Distinction
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512451/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.121
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars